Philadelphia chromosome-positive acute lymphoblastic leukemia by Forghieri, Fabio et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=yhem20
Hematology
ISSN: (Print) 1607-8454 (Online) Journal homepage: https://www.tandfonline.com/loi/yhem20
Philadelphia chromosome-positive Acute
Lymphoblastic Leukemia
Fabio Forghieri, Mario Luppi & Leonardo Potenza
To cite this article: Fabio Forghieri, Mario Luppi & Leonardo Potenza (2015) Philadelphia
chromosome-positive Acute Lymphoblastic Leukemia, Hematology, 20:10, 618-619, DOI:
10.1179/1024533215Z.000000000402
To link to this article:  https://doi.org/10.1179/1024533215Z.000000000402
Published online: 17 Nov 2015.
Submit your article to this journal 
Article views: 654
View related articles 
View Crossmark data
Citing articles: 4 View citing articles 
Philadelphia chromosome-positive Acute
Lymphoblastic Leukemia
Introduction
Acute lymphoblastic leukemia (ALL) is a hetero-
geneous malignancy characterized by the accumu-
lation of immature lymphoid cells in bone marrow
(BM), peripheral blood (PB) and other organs. ALL
is the most common cancer in children, but approxi-
mately one third of cases occur in adults, with an
estimated annual incidence of about one in
100,000 persons.
Philadelphia (Ph) chromosome is the most
common cytogenetic abnormality found in adult
B-cell lineage ALL. The incidence of Ph+ ALL
increases with age, from less than 5% in younger chil-
dren to 20-30% in older adults, with a peak incidence
in patients aged 35-50 years. The Ph chromosome is
a translocation, t(9;22), between ABL-1 oncogene on
the long arm of chromosome 9 and a breakpoint
cluster region (BCR) on the long arm of chromosome
22, resulting in the fusion gene transcript BCR-ABL,
which encodes an oncogenic protein with constitu-
tively active tyrosine kinase activity, leading to altera-
tion of multiple intracellular signalling pathways, self-
renewal, proliferation and tumor growth. The p190
BCR-ABL transcript may be documented in 50-80%
of adults with Ph+ ALL, whereas the p210 transcript,
commonly observed in chronic myeloid leukemia
(CML), is found in the remaining Ph+ ALL population.
Co-presence of both p190 and p210 BCR-ABL tran-
scripts may also be found.
Symptoms and signs
The clinical presentation of Ph+ ALL, similarly to
other forms of ALL, is largely non-specific and
may include fatigue and dyspnea, dizziness, infec-
tions, constitutional symptoms (fever, night sweats,
weight loss) and bleeding. Neurologic symptoms,
secondary to leukemia central nervous system invol-
vement, are more frequent at relapse.
Lymphadenopathy, splenomegaly and/or hepato-
megaly may be observed on physical examination
in approximately 20% of the patients.
Tests
Upon laboratory suspicion of leukemia, based on
clinical presentation and complete blood count
with differentials, BM aspirate and trephine biopsy
should be performed. The diagnosis of ALL requires
the demonstration of 20% or greater BM lympho-
blasts on morphologic and immunophenotypic
examinations. Identification of specific recurrent
either cytogenetic or molecular abnormalities is criti-
cal for disease evaluation, optimal risk stratification
and treatment planning. The presence of Ph
chromosome/BCR-ABL fusion transcript should
urgently be investigated using conventional cytoge-
netics, interphase fluorescence in situ hybridization
(FISH) and molecular assays on PB and BM
samples. Quantitative polymerase chain reaction
(RQ-PCR) should also be performed to document,
at diagnosis, the absolute number of p190 or p210
fusion transcripts, relative to a housekeeping gene.
The presence of additional cytogenetic abnormal-
ities is also commonly observed.
Prognosis and treatment
Until recently, Ph+ ALL adults, undergoing standard
chemotherapy, had a dismal prognosis with
long-term survival rates of approximately 10-20%.
Allogeneic hematopoietic stem cell transplantation
(alloHSCT) from a HLA-matched donor, performed
in few selected patients in complete remission (CR),
significantly decreased the relapse rate, leading to
a long-term survival ranging from 40% to 60%. The
development of tyrosine kinase inhibitors (TKIs),
which inhibit BCR-ABL and other constitutively acti-
vated aberrant tyrosine kinases, has revolutionized
therapy and outcomes of patients with CML and
Ph+ALL. However, imatinib, the first BCR-ABL inhibi-
tor which obtained clinical approval, produced only
modest and short-lasting responses in patients with
previously treated, relapsed Ph+ ALL. Conversely,
imatinib, either alone or combined with steroids/che-
motherapy, may induce CR in >90% adults with
newly diagnosed Ph+ ALL, with minimal toxicity. It
is widely recommended to use a TKI in all newly diag-
nosed Ph+ ALL patients to increase CR rate, prolong
time to relapse, improve alloHSCT eligibility and
improve leukemia-free survival. Upon achievement
of CR, treatment should be continued until disease
progression or alloHSCT. There is no clinical
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evidence to support intermittent drug administration
or drug holidays. These recommendations apply to
both transplant eligible and non-transplant eligible
patients, including elderly subjects. The clinical
outcome of Ph+ ALL has significantly improved
over the last 10 years, with up to 60% 5-year overall
survival rates in patients undergoing alloHSCT, from
matched related or unrelated donor, in first CR after
TKIs-based remission induction/consolidation
treatments.
Unfortunately, resistance to one or more TKIs may
emerge because of BCR-ABL-dependent and
BCR-ABL-independent mechanisms. Of note,
BCR-ABL-dependent mechanisms include gene
amplifications and tyrosine-kinase domain
mutations, disrupting binding to the drug target.
One third of patients presents, at diagnosis, with
small subpopulations containing BCR-ABL
mutations, whereas mutations may also be acquired
or emerge under selection pressure during TKIs
treatment. For patients with relapsed/refractory
Ph+ ALL, while receiving imatinib, a second- or sub-
sequent-generation TKI (dasatinib, nilotinib, bosuti-
nib and ponatinib), with or without further
additional chemotherapy should be administered,
according to the results of mutational analysis of
BCR-ABL transcript. Of note, ponatinib has activity
against the highly-resistant T315I mutation and is
effective in treating patients with resistant or pro-
gressive disease after multiple TKIs. For patients
with disease relapsing after alloHSCT, donor lym-
phocyte infusion (DLI) and/or a second alloHSCT
may be therapeutic options. Furthermore, exper-
imental immunotherapeutic approaches with blina-
tumomab, an antibody BiTE anti-CD19, or chimeric
antigen receptor (CAR) T cells may be considered.
Quantitative assessment of BCR-ABL transcript
levels by molecular assays to monitor minimal
residual disease (MRD) in patients achieving hemato-
logic CR has strong prognostic significance. For
patients not candidate to receive alloHSCT, serial
monitoring during initial therapy is relevant because
it may prompt a switch of TKI treatment before mor-
phologic relapse. Moreover, BCR-ABL monitoring
may have immediate impact after alloHSCT to guide
specific approaches, such as immunosuppression
reduction, re-starting of TKIs administration or DLI.
Of interest, BCR-ABL-specific T-cells may emerge
in patients with Ph+ ALL under TKIs treatment and
synergize with TKIs for remission maintenance
because they are associated with lower MRD values
and can directly mediate specific lysis of Ph+ blasts.
The use of the aforementioned newer generations
TKIs, with or without additional chemotherapy, has
been explored in clinical trials for patient with
newly diagnosed Ph+ ALL, obtaining CR with
minimal toxicity. However, the choice of optimal
TKI for remission induction/consolidation treat-
ments remains to be elucidated. Although molecular
CR may be obtained in some patients with TKIs
alone, long-term outcome without intensive che-
motherapy and alloHSCT is currently unknown. To
date, available information cannot support the omis-
sion of alloHSCT in younger fit patients, regardless
of MRD status.
In conclusion, the wide clinical use of TKIs has
significantly improved remission duration and prog-
nosis of Ph+ ALL patients, but further clinical inves-
tigations are warranted to clarify some therapeutic
issues.
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